A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Study Details
Study Description
Brief Summary
This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 4 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Atezolizumab Participants will continue to receive atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) in accordance with local prescribing information till the participant continues to derive clinical benefit or until death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first. |
Drug: Atezolizumab
Atezolizumab will be administered as monotherapy or combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study). Dosing regimen will be in accordance with the parent study and local prescribing information.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants With Continued Access to Atezolizumab-Based Therapy and/or Comparator Agent(s) [Day 1 up to maximum 10 years]
Secondary Outcome Measures
- Percentage of Participants With Serious Adverse Events (SAEs) by Severity Determined According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 [Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)]
- Percentage of Participants With Adverse Events of Special Interest by Severity Determined According to NCI CTCAE Version 4.0 [Day 1 up to 90 days after last dose of study treatment (last dose=till clinical benefit or until death, withdrawal of consent, unacceptable toxicity, pregnancy, non-compliance, or termination by Sponsor, whichever occurs first) (up to maximum 10 years)]
- Time from Randomization or Treatment Initiation to Death due to any Cause for IMpower133 Participants Only [Day 1 (as indicated in parent study protocol) until death due to any cause (up to maximum 10 years)]
Eligibility Criteria
Criteria
Inclusion Criteria:
Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study (and survival follow up for pattients who roll over from
IMpower133):
-
Eligible for continuing or crossing over to atezolizumab-based therapy at the time of the parent-study closure as per the parent study or eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study at the time of the parent-study closure as per the parent study, with no access to commercially available comparator agent
-
First dose of study treatment in the extension study will be received within 7 days of the treatment interruption window allowed by the parent study
-
Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of parent-study closure as assessed by the investigator
-
Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential
Specific criteria for patients from the IMpower133 parent study only who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:
- Discontinuation of atezolizumab-based therapy in the IMpower133 parent study and in survival follow- up at the time of IMpower133 parent study closure, or eligible for continuing or crossing over to atezolizumab-based therapy as per the IMpower133 parent protocol and have access to commercially available atezolizumab (Tecentriq) outside this extension study at the time of the IMpower133 parent-study closure
Exclusion Criteria:
Specific criteria for patients who continue treatment as well as safety and survival follow-up in the extension study:
-
Meet of any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in the extension study
-
Study treatment is commercially marketed in the patient's country for the patient specific disease and is accessible to the patient
-
Time between the last dose of treatment received in parent study and first dose in extension study is longer than the interruption period (± 7 days) allowed in the parent study
-
Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in the extension study
-
Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study (if applicable)
-
Any unresolved or irreversible toxicities during the parent study that required permanent discontinuation of study treatment, in accordance to the parent study or local prescribing information
-
Ongoing SAE(s) that has not resolved to baseline level or Grade less than or equal to (<=) 1 from the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study
-
Any serious uncontrolled concomitant disease that would contraindicate the use of study treatment at the time of the extension study or that would place the participant at high risk for treatment-related complications
-
Concurrent participation in any therapeutic clinical trial (other than the parent study)
Specific criteria for patients who do not continue treatment in the extension study and/or receive commercially available atezolizumab (Tecentriq) outside this extension study and continue safety and survival follow-up only in the extension study:
- Discontinuation of comparator in parent study and in survival follow-up at the time of parent study closure
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | HonorHealth Research Institute - Bisgrove | Scottsdale | Arizona | United States | 85258 |
2 | UCLA | Los Angeles | California | United States | 90024 |
3 | Angeles Clinic & Rsch Inst | Los Angeles | California | United States | 90025 |
4 | Kaiser Permanente - San Diego (Zion Ave) | San Marcos | California | United States | 92078 |
5 | University Of Colorado | Aurora | Colorado | United States | 80045 |
6 | Rocky Mountain Cancer Ctr - Denver (Williams) | Denver | Colorado | United States | 80218 |
7 | Smilow Cancer Hospital at Yale New Haven | New Haven | Connecticut | United States | 06510 |
8 | Georgetown University Medical Center Lombardi Cancer Center | Washington | District of Columbia | United States | 20007 |
9 | Florida Cancer Specialists - Fort Myers (Broadway) | Fort Myers | Florida | United States | 33901 |
10 | Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida | United States | 34952 |
11 | Florida Cancer Specialists. | Saint Petersburg | Florida | United States | 33705 |
12 | H. Lee Moffitt Cancer Center and Research Inst. | Tampa | Florida | United States | 33612 |
13 | Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Carrollton | Georgia | United States | 30117 |
14 | Northwestern University; Robert H. Lurie Comp Can Ctr | Chicago | Illinois | United States | 60611 |
15 | Rush University Medical Center | Chicago | Illinois | United States | 60612-3244 |
16 | University Of Chicago Medical Center; Section Of Hematology/Oncology | Chicago | Illinois | United States | 60637 |
17 | Ingalls Memorial Hospital | Harvey | Illinois | United States | 60426 |
18 | Illinois Cancer Care | Peoria | Illinois | United States | 61615 |
19 | New England Cancer Specialists | Scarborough | Maine | United States | 04074 |
20 | Johns Hopkins Univ Med Center | Baltimore | Maryland | United States | 21231 |
21 | Maryland Oncology Hematology, P.A. | Columbia | Maryland | United States | 21044 |
22 | Massachusetts General Hospital. | Boston | Massachusetts | United States | 02114 |
23 | Dana Farber Cancer Inst. ; Dept. of Medical Oncology | Boston | Massachusetts | United States | 02115 |
24 | Karmanos Cancer Institute | Detroit | Michigan | United States | 48201 |
25 | US oncology research at Minnesota Oncology | Saint Paul | Minnesota | United States | 55102 |
26 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
27 | Comprehensive Cancer Centers of Nevada - Eastern Avenue | Las Vegas | Nevada | United States | 89169 |
28 | Summit Medical Center | Florham Park | New Jersey | United States | 07932 |
29 | New York Oncology Hematology, P.C. | Albany | New York | United States | 12206 |
30 | Memorial Sloan-Kettering Cancer Center | Commack | New York | United States | 11725 |
31 | Beth Israel Medical Center; Division of Digestive Diseases | New York | New York | United States | 10003 |
32 | Carolina BioOncology Institute, PLCC | Huntersville | North Carolina | United States | 28078 |
33 | Cleveland Clinic | Cleveland | Ohio | United States | 44106 |
34 | Oncology Associates of Oregon, P.C | Eugene | Oregon | United States | 97401 |
35 | Northwest Cancer Specialists - Portland (N Broadway) | Portland | Oregon | United States | 97227 |
36 | Penn State Hershey Cancer Institute | Hershey | Pennsylvania | United States | 17033 |
37 | Allegheny Cancer Center | Pittsburgh | Pennsylvania | United States | 15212 |
38 | Sarah Cannon Res Inst; TN Onc | Nashville | Tennessee | United States | 37203 |
39 | Vanderbilt Univ Medical Ctr | Nashville | Tennessee | United States | 37203 |
40 | Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | United States | 75246 |
41 | Tyler Cancer Center | Fort Worth | Texas | United States | 76177 |
42 | Virginia Oncology Associates - Lake Wright Cancer Center | Norfolk | Virginia | United States | 23502 |
43 | Blue Ridge Cancer Care | Roanoke | Virginia | United States | 24014 |
44 | University of Washington Seattle Cancer Care Alliance | Seattle | Washington | United States | 98195 |
45 | Northwest Medical Specialties | Tacoma | Washington | United States | 98405 |
46 | Fundación CENIT para la Investigación en Neurociencias | Buenos Aires | Argentina | C1125ABD | |
47 | Chris O'Brien Lifehouse | Camperdown | New South Wales | Australia | 2050 |
48 | Princess AleXandra Hospital; Department of Medical Oncology | Woolloongabba | Queensland | Australia | 4102 |
49 | SMZ - Baumgartner Hohe, Otto-Wagner-Spital; 2.Interne Lungenabteilung | Wien | Austria | 1140 | |
50 | Krankenhaus Nord - Klinik Floridsdorf; Abteilung Pulmologie | Wien | Austria | 1210 | |
51 | AZ Glorieux- vzw Werken Glorieux | Ronse | Belgium | 9600 | |
52 | Sint Augustinus Wilrijk | Wilrijk | Belgium | 2610 | |
53 | Hospital de Cancer de Barretos | Barretos | SP | Brazil | 14784-400 |
54 | Instituto do Cancer do Estado de Sao Paulo - ICESP | Sao Paulo | SP | Brazil | 01246-000 |
55 | Fundacao Antonio Prudente | Sao Paulo | SP | Brazil | 01509-900 |
56 | Multiprofile Hospital for Active Treatment Serdika EOOD; Medical Oncology Department | Sofia | Bulgaria | 1632 | |
57 | Royal Victoria Hospital | Barrie | Ontario | Canada | L4M 6M2 |
58 | William Osler Health Centre | Etobicoke | Ontario | Canada | M9V 1R8 |
59 | Lakeridge Health Corporation-Oshawa; Oncology clinic | Oshawa | Ontario | Canada | L1G 2B9 |
60 | Sunnybrook Odette Cancer Centre; Clinical Trials | Toronto | Ontario | Canada | M4N 3M5 |
61 | Princess Margaret Cancer Center | Toronto | Ontario | Canada | M5G 1Z5 |
62 | Cite de La Sante de Laval; Hemato-Oncologie | Laval | Quebec | Canada | H7M 3L9 |
63 | Jewish General Hospital | Montreal | Quebec | Canada | H3T 1E2 |
64 | Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas | Recoleta | Chile | 8420383 | |
65 | Masarykuv onkologicky ustav | Brno | Czechia | 656 53 | |
66 | Thomayerova nemocnice | Praha 4 - Krc | Czechia | 140 59 | |
67 | Hopital Jean Minjoz; Pneumologie | Besancon | France | 25030 | |
68 | Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie | Grenoble | France | 38043 | |
69 | Centre Leon Berard; Departement Oncologie Medicale | Lyon | France | 69373 | |
70 | Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique | Marseille | France | 13915 | |
71 | Centre René Gauducheau - cancer Nantes - Atlantique; Service Oncologie Médicale | Nantes | France | 44805 | |
72 | Centre Antoine Lacassagne, Centre de Lutte Contre le Cancer (CLCC) de Nice | Nice | France | 06189 | |
73 | Hopital Saint Louis; Oncologie Medicale | Paris | France | 75475 | |
74 | GH Paris Saint Joseph; Pneumologie | Paris | France | 75674 | |
75 | Hopital Tenon;Pneumologie | Paris | France | 75970 | |
76 | Centre Hospitalier Lyon Sud | Pierre Benite | France | 69495 | |
77 | CH de Saint Quentin | Saint Quentin | France | 2100 | |
78 | Centre Medico-Chirurgical Foch; Service de Pneumologie | Suresnes | France | 92151 | |
79 | CHU de Toulouse - Hôpital Larrey; Service de pneumologie et oncologie pneumologique | Toulouse cedex 9 | France | 31100 | |
80 | Institut Gustave Roussy; Sitep | VILLEJUIF Cedex | France | 94805 | |
81 | Klinikum d.Universität München Campus Großhadern | München | Germany | 81377 | |
82 | Semmelweis Egyetem X; Pulmonologiai Klinika | Budapest | Hungary | 1083 | |
83 | Tudogyogyintezet Torokbalint | Torokbalint | Hungary | 2045 | |
84 | Belinson Medical Center | Petah Tikva | Israel | 4922297 | |
85 | Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica | Napoli | Campania | Italy | 80131 |
86 | Azienda Ospedaliera A. Cardarelli; Dip. Oncopneumoematologico | Napoli | Campania | Italy | 80131 |
87 | Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale | Napoli | Campania | Italy | 80131 |
88 | A.O. Universitaria Policlinico Di Modena; Oncologia | Modena | Emilia-Romagna | Italy | 41100 |
89 | Università Cattolica Del S Cuore | Roma | Lazio | Italy | 00168 |
90 | ASL 3 Genovese | Genova | Liguria | Italy | 16125 |
91 | IRCCS AOU San Martino - IST | Genova | Liguria | Italy | 16132 |
92 | Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1 | Milano | Lombardia | Italy | 20133 |
93 | Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2 | Milano | Lombardia | Italy | 20133 |
94 | Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica | Milano | Lombardia | Italy | 20141 |
95 | ASST DI MONZA; Oncologia Medica | Monza | Lombardia | Italy | 20900 |
96 | A.O.U. Maggiore della Carità | Novara | Piemonte | Italy | 28100 |
97 | Az. Osp. S. Luigi Gonzaga; Malattie Apparato Respiratorio 5 Ad Indirizzo Oncologico | Orbassano | Piemonte | Italy | 10043 |
98 | Policlinico Vittorio Emanuele | Catania | Sicilia | Italy | 95123 |
99 | Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia | Arezzo | Toscana | Italy | 52100 |
100 | A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii | Pisa | Toscana | Italy | 56124 |
101 | Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica | Siena | Toscana | Italy | 53100 |
102 | Ospedale Santa Maria Della; Misericordia Di Perugia; Farmacia Ospedaliera | Perugia | Umbria | Italy | 06129 |
103 | IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II | Padova | Veneto | Italy | 35128 |
104 | Shikoku Cancer Center | Ehime | Japan | 791-0280 | |
105 | Iwate Medical University Hospital; Urology | Iwate | Japan | 028-3695 | |
106 | Sendai Kousei Hospital | Miyagi | Japan | 980-0873 | |
107 | Niigata Cancer Center Hospital | Niigata | Japan | 951-8566 | |
108 | Okayama University Hospital; Respiratory and Allergy Medicine | Okayama | Japan | 700-8558 | |
109 | Toranomon Hospital; Medical Oncology | Tokyo | Japan | 105-8470 | |
110 | The Cancer Institute Hospital of JFCR, Respiratory Medicine | Tokyo | Japan | 135-8550 | |
111 | Wakayama Medical University Hospital | Wakayama | Japan | 641-8510 | |
112 | National Cancer Center | Goyang-si | Korea, Republic of | 10408 | |
113 | Chonnam National University Hwasun Hospital | Jeollanam-do | Korea, Republic of | 58128 | |
114 | Seoul National University Bundang Hospital | Seongnam-si | Korea, Republic of | 13605 | |
115 | Samsung Medical Center | Seoul | Korea, Republic of | 06351 | |
116 | NKI/AvL | Amsterdam | Netherlands | 1066 CX | |
117 | Auckland city hospital; Auckland Regional Cancer Centre and Blood Service | Auckland | New Zealand | 1023 | |
118 | Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii | Gdansk | Poland | 80-214 | |
119 | Oddział Onkologii Klinicznej i Chemioterapii Szpitala ELBLĄSKA | Warszawa | Poland | 01-748 | |
120 | Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers | Warszawa | Poland | 02-781 | |
121 | Hospital de Santa Maria; Servico de Oncologia Medica | Lisboa | Portugal | 1649-035 | |
122 | Centro Hospitalar do Porto - Hospital de Santo António; Oncologia | Porto | Portugal | 4099-001 | |
123 | Institut Oncologic Ion Chiricuta; Departament Radioterapie | Cluj-napoca | Romania | 400015 | |
124 | ONCOMED - Medical Centre | Timisoara | Romania | 300239 | |
125 | Moscow City Oncology Hospital #62 | Moscovskaya Oblast | Moskovskaja Oblast | Russian Federation | 143423 |
126 | Clinic for Pulmonology, Clinical Center of Serbia | Belgrade | Serbia | 11000 | |
127 | University Hospital Medical Center Bezanijska kosa | Belgrade | Serbia | 11080 | |
128 | Institute of Oncology Ljubljana | Ljubljana | Slovenia | 1000 | |
129 | Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia | Badalona | Barcelona | Spain | 08916 |
130 | Hospital Universitario Reina Sofia; Servicio de Oncologia | Córdoba | Cordoba | Spain | 14004 |
131 | Hospital Son Llatzer; Servicio de Oncologia | Palma de Mallorca | Islas Baleares | Spain | 07198 |
132 | Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia | Las Palmas de Gran Canaria | LAS Palmas | Spain | 35016 |
133 | Clinica Universitaria de Navarra; Servicio de Oncologia | Pamplona | Navarra | Spain | 31008 |
134 | Hospital del Mar; Servicio de Oncologia | Barcelona | Spain | 08003 | |
135 | Hospital Univ Vall d'Hebron; Servicio de Oncologia | Barcelona | Spain | 08035 | |
136 | Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department | Barcelona | Spain | 08036 | |
137 | Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia | Barcelona | Spain | 08041 | |
138 | Institut Catala d Oncologia Hospital Duran i Reynals | Barcelona | Spain | 08908 | |
139 | Hospital San Pedro De Alcantara; Servicio de Oncologia | Caceres | Spain | 10003 | |
140 | Complejo Hospitalario de Jaen | Jaen | Spain | 23007 | |
141 | Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología | La Coruña | Spain | 15006 | |
142 | Hospital Lucus Augusti; Servicio de Oncologia | Lugo | Spain | 27003 | |
143 | Hospital General Universitario Gregorio Marañon; Servicio de Oncologia | Madrid | Spain | 28007 | |
144 | Hospital Ramon y Cajal; Servicio de Oncologia | Madrid | Spain | 28034 | |
145 | Hospital Universitario Clínico San Carlos; Servicio de Oncologia | Madrid | Spain | 28040 | |
146 | Hospital Universitario 12 de Octubre; Servicio de Oncologia | Madrid | Spain | 28041 | |
147 | Hospital Universitario La Paz; Servicio de Oncologia | Madrid | Spain | 28046 | |
148 | HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia | Madrid | Spain | 28050 | |
149 | Hospital Regional Universitario Carlos Haya; Servicio de Oncologia | Malaga | Spain | 29011 | |
150 | Hospital Universitario Virgen del Rocio; Servicio de Oncologia | Sevilla | Spain | 41013 | |
151 | Hospital General Universitario de Valencia; Servicio de oncologia | Valencia | Spain | 46014 | |
152 | Hospital NisA 9 de Octubre | Valencia | Spain | 46015 | |
153 | CHUV; Departement d'Oncologie | Lausanne | Switzerland | 1011 | |
154 | Changhua Christian Hospital; Internal Medicine | Changhua | Taiwan | 500 | |
155 | China Medical University Hospital; Urology | Taichung | Taiwan | 40447 | |
156 | National Taiwan Uni Hospital; Dept of Oncology | Taipei | Taiwan | 100 | |
157 | Chulalongkorn Hospital; Medical Oncology | Bangkok | Thailand | 10330 | |
158 | Ramathibodi Hospital; Medicine/Oncology | Bangkok | Thailand | 10400 | |
159 | Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology | Bangkok | Thailand | 10700 | |
160 | Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi | Edirne | Turkey | 22030 | |
161 | Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology | Istanbul | Turkey | 34300 | |
162 | Hacettepe Uni Medical Faculty Hospital; Oncology Dept | Sihhiye/Ankara | Turkey | 06230 | |
163 | Municipal Institution Podilskiy Regional Center of Oncology; Department of Chemotherapy | Vinnytsia | Podolia Governorate | Ukraine | 21029 |
164 | Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU; Chair of Oncology and Medical Radiology | Dnipropetrovsk | Ukraine | 49102 | |
165 | The Clatterbridge Cancer Centre NHS Foundation Trust | Liverpool | United Kingdom | L7 8YA | |
166 | Barts & London School of Med; Medical Oncology | London | United Kingdom | EC1A 7BE | |
167 | Royal Free Hospital; Oncology & Haematology | London | United Kingdom | NW3 2QG | |
168 | St George's Hospital; Oncology | London | United Kingdom | SW17 0QT | |
169 | Royal Marsden Hospital - London | London | United Kingdom | SW3 6JJ | |
170 | Charing Cross Hospital; Medical Oncology. | London | United Kingdom | W6 8RF | |
171 | Christie Hospital NHS Trust | Manchester | United Kingdom | M20 4BX | |
172 | Nottingham City Hospital; Oncology | Nottingham | United Kingdom | NG5 1PB | |
173 | Royal Marsden Hospital - Surrey | Surrey | United Kingdom | SM2 5PT |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BO39633
- 2016-005189-75